Evoke Pharma, Inc.
EVOK
$3.30
$0.216.80%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -1.19M | -1.31M | -1.27M | -1.58M | -1.99M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 403.60K | 506.90K | 1.90K | 378.70K | 421.70K |
| Change in Net Operating Assets | -450.90K | -13.20K | 444.70K | -1.38M | 459.60K |
| Cash from Operations | -1.24M | -818.70K | -820.60K | -2.58M | -1.11M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 3.48M | 3.00M | 295.70K | 7.97M | -- |
| Repurchase of Common Stock | 0.00 | -200.00 | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 15.50K | -15.50K | 0.00 | -426.30K | -119.30K |
| Cash from Financing | 3.50M | 2.98M | 295.70K | 7.54M | -119.30K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2.26M | 2.16M | -524.90K | 4.96M | -1.23M |